Skip to main content
Top
Published in: AIDS and Behavior 4/2015

01-04-2015 | Original Paper

Comparison of Pharmacy-Based Measures of Adherence to Antiretroviral Therapy as Predictors of Virological Failure

Authors: Cassidy E. Henegar, Daniel Westreich, Mhairi Maskew, M. Alan Brookhart, William C. Miller, Pappie Majuba, Annelies Van Rie

Published in: AIDS and Behavior | Issue 4/2015

Login to get access

Abstract

We compared multiple pharmacy refill-based adherence indicators for antiretroviral therapy, as well as thresholds for defining non-adherent behavior, based on ability to predict virological failure. A total of 29,937 pharmacy visits with corresponding viral load assessments were contributed by 8,695 patients attending a large clinic in Johannesburg, South Africa. Indicators based on pill coverage and timing of refill pickup performed comparably using the strictest thresholds for adherence [100 % pill coverage: odds ratio (OR) (95 % confidence interval (CI)) : 1.26 (1.15, 1.39); prescription picked up on or before scheduled refill date: 1.27 (1.16,1.38)]. For both types of indicators, the association between non-adherence and virological failure increased as the threshold defining adherent behavior was lowered. All measures demonstrated high specificity (range 84–98 %), but low sensitivity (5–19 %). In this setting, patients identified as non-adherent using pharmacy-based indicators are likely correctly classified and in need of interventions to improve compliance. Pharmacy based measures alone, however, are inadequate for identifying most cases of nonadherence.
Appendix
Available only for authorised users
Literature
1.
go back to reference de Garcia Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. JAIDS. 2002;30(1):105–10. de Garcia Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. JAIDS. 2002;30(1):105–10.
2.
go back to reference Kredo T, Walt J, Siegfried N, Cohen K. Therapeutic drug monitoring of antiretrovirals for people with HIV. Cochrane DB Syst Rev. 2009; 8(3): Article Number CD007268. Kredo T, Walt J, Siegfried N, Cohen K. Therapeutic drug monitoring of antiretrovirals for people with HIV. Cochrane DB Syst Rev. 2009; 8(3): Article Number CD007268.
3.
go back to reference Lima V, Harrigan R, Murray M, et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS. 2008;22:2371–80.CrossRefPubMed Lima V, Harrigan R, Murray M, et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS. 2008;22:2371–80.CrossRefPubMed
4.
go back to reference Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–60.CrossRefPubMed Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–60.CrossRefPubMed
5.
go back to reference Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197(Suppl 3):S272–8.CrossRefPubMed Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197(Suppl 3):S272–8.CrossRefPubMed
6.
go back to reference World Health Organization. Patient monitoring guidelines for HIV care and antiretroviral therapy (ART). Geneva: WHO; 2006. World Health Organization. Patient monitoring guidelines for HIV care and antiretroviral therapy (ART). Geneva: WHO; 2006.
7.
go back to reference McMahon JH, Jordan MR, Kelley K, et al. Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis. 2012;52(4):493–506.CrossRef McMahon JH, Jordan MR, Kelley K, et al. Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis. 2012;52(4):493–506.CrossRef
8.
go back to reference Grossberg R, Gross R. Use of pharmacy refill data as a measure of antiretroviral adherence. Curr HIV/AIDS Rep. 2007;4:187–91.CrossRefPubMed Grossberg R, Gross R. Use of pharmacy refill data as a measure of antiretroviral adherence. Curr HIV/AIDS Rep. 2007;4:187–91.CrossRefPubMed
9.
go back to reference Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40:1280–8.CrossRefPubMed Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40:1280–8.CrossRefPubMed
10.
go back to reference Grossberg R, Zhang Y, Gross R. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol. 2004;57:1107–10.CrossRefPubMed Grossberg R, Zhang Y, Gross R. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol. 2004;57:1107–10.CrossRefPubMed
11.
go back to reference Fox M, Maskew M, Macphail AP, et al. Cohort profile: the Themba Lethu Clinical cohort, Johannesburg, South Africa. Int J Epidemiol. 2013;42(2):430–9.CrossRefPubMedCentralPubMed Fox M, Maskew M, Macphail AP, et al. Cohort profile: the Themba Lethu Clinical cohort, Johannesburg, South Africa. Int J Epidemiol. 2013;42(2):430–9.CrossRefPubMedCentralPubMed
12.
go back to reference Westreich D, Cole SR, Nagar S, Maskew M, van der Horst C, Sanne I. Pregnancy and virologic response to antiretroviral therapy in South Africa. PLoS ONE. 2011;6(8):e22778.CrossRefPubMedCentralPubMed Westreich D, Cole SR, Nagar S, Maskew M, van der Horst C, Sanne I. Pregnancy and virologic response to antiretroviral therapy in South Africa. PLoS ONE. 2011;6(8):e22778.CrossRefPubMedCentralPubMed
13.
go back to reference Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in Sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006;296(6):679–90.CrossRefPubMed Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in Sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006;296(6):679–90.CrossRefPubMed
14.
go back to reference Riddler S, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358(20):2095–106.CrossRefPubMed Riddler S, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358(20):2095–106.CrossRefPubMed
15.
go back to reference Westreich D, Cole SR, Funk MJ, Brookhart MA, Sturmer T. The role of the c-statistic in variable selection for propensity score models. Pharmacoepidemiol Drug Saf. 2011;20(3):317–20.CrossRefPubMedCentralPubMed Westreich D, Cole SR, Funk MJ, Brookhart MA, Sturmer T. The role of the c-statistic in variable selection for propensity score models. Pharmacoepidemiol Drug Saf. 2011;20(3):317–20.CrossRefPubMedCentralPubMed
16.
go back to reference El-Khatib Z, Ekstrom AM, Coovadia A, et al. Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa- a prospective cohort study. BMC Public Health. 2011;11:88.CrossRefPubMedCentralPubMed El-Khatib Z, Ekstrom AM, Coovadia A, et al. Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa- a prospective cohort study. BMC Public Health. 2011;11:88.CrossRefPubMedCentralPubMed
17.
go back to reference El-Khatib Z, Ekstrom AM, Ledwaba J, et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS. 2010;24:1679–87.CrossRefPubMedCentralPubMed El-Khatib Z, Ekstrom AM, Ledwaba J, et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS. 2010;24:1679–87.CrossRefPubMedCentralPubMed
18.
go back to reference Ross-Degnan D, Pierre-Jacques M, Zhang F, et al. Measuring adherence to antiretroviral treatment in resource -poor settings: the clinical validity of key indicators. BMC Health Serv Res. 2010;10:42.CrossRefPubMedCentralPubMed Ross-Degnan D, Pierre-Jacques M, Zhang F, et al. Measuring adherence to antiretroviral treatment in resource -poor settings: the clinical validity of key indicators. BMC Health Serv Res. 2010;10:42.CrossRefPubMedCentralPubMed
19.
go back to reference Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385–94.CrossRefPubMed Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385–94.CrossRefPubMed
20.
go back to reference Bangsberg DR, Hecht FM, Charlebois ED, Chesney M, Moss A. Comparing objective measures of adherence to HIV antiretroviral therapy: electronic medication monitors and unannounced pill counts. AIDS Behav. 2001;5(3):275–81.CrossRef Bangsberg DR, Hecht FM, Charlebois ED, Chesney M, Moss A. Comparing objective measures of adherence to HIV antiretroviral therapy: electronic medication monitors and unannounced pill counts. AIDS Behav. 2001;5(3):275–81.CrossRef
21.
go back to reference Pepe M, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004;159(9):882–90.CrossRefPubMed Pepe M, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004;159(9):882–90.CrossRefPubMed
23.
go back to reference Chesney MA. The elusive gold standard: future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S149–55.CrossRefPubMed Chesney MA. The elusive gold standard: future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S149–55.CrossRefPubMed
Metadata
Title
Comparison of Pharmacy-Based Measures of Adherence to Antiretroviral Therapy as Predictors of Virological Failure
Authors
Cassidy E. Henegar
Daniel Westreich
Mhairi Maskew
M. Alan Brookhart
William C. Miller
Pappie Majuba
Annelies Van Rie
Publication date
01-04-2015
Publisher
Springer US
Published in
AIDS and Behavior / Issue 4/2015
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-014-0953-2

Other articles of this Issue 4/2015

AIDS and Behavior 4/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.